Discontinuation and dose reduction of rituximab in relapsing –remitting multiple sclerosis

ConclusionsThis study indicates that rituximab has long-term effects on inflammatory disease activity and that disease reactivation is rare in MS patients who discontinued treatment for any reason. It also suggests that treatment with low-dose rituximab (< 1000 mg yearly) is sufficient to maintain suppression of inflammatory disease activity in patients with stable disease.

http://link.springer.com/10.1007/s00415-021-10399-8

Source: Journal of Neurology - January 21, 2021 Category: Neurology Source Type: research